Thiopurines with low-dose allopurinol (ThiLDA) —a prospective clinical one-way crossover trial
ConclusionCombination therapy with 50 mg allopurinol led to a decrease of 6-TGN levels compared with 100 mg allopurinol. Disease activity, side effects, and patient experience, however, were similar between allopurinol 100 and 50 mg. UC patients seem to benefit and prefer lower doses whereas the contrary is seen in CD patients.Trial registrationEudraCT trial registry - number2016-001638-84
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Allopurinol | Crohn's Disease | Drugs & Pharmacology | Inflammatory Bowel Disease | Study | Ulcerative Colitis